Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Overview of Randomized Clinical Trials
Tricoci, Pierluigi × Newby, L. Kristin Hasselblad, Vic Kong, David F Giugliano, Robert P White, Harvey D Theroux, Pierre Stone, Gregg W Moliterno, David J Van de Werf, Frans Armstrong, Paul W Prabhakaran, Dorairaj Rasoul, Saman Bolognese, Leonardo Durand, Eric Braunwald, Eugene Califf, Robert M Harrington, Robert A #
Lippincott Williams & Wilkins
Circulation-Cardiovascular Quality and Outcomes vol:4 issue:4 pages:448-458
Background-The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes (NSTE ACS) has been studied in multiple randomized clinical trials. We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials.